Scalable psychedelic therapy for depression

Alphion is developing a short-duration, best-in-class neuroplastogen for treatment-resistant depression and other difficult-to-treat neuropsychiatric diseases.

Why duration matters

A single dose of psilocybin has produced rapid reductions in depressive symptoms in people with treatment-resistant depression.1 Classic psychedelics act for six hours or more, and a clinician has to stay with the patient for the whole session. That limits how many people a clinic can treat.

Alphion’s compound is designed to act for a much shorter time, so that a treatment session fits into an ordinary clinic schedule.

Contact

info@alphion.de
Alphion UG (haftungsbeschränkt)
Richard-Wagner-Straße 26
69214 Eppelheim, Germany

Dr. Christian Klein
Managing Director